Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Lung Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
80 drugs · 288 active trials
21 drugs · 605 active trials
51 drugs · 1,369 active trials
Outside the funnel: Phase not stated 2 · Withdrawn 2. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 19 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Claturafenib | Phase 1 | Phase 1 | 2 | 0 | 0 | 2 | 0 | — | — | Jul 5, 2022 |
| Elimusertib | Phase 1 | Phase 1 | 2 | 0 | 0 | 2 | 0 | — | — | Aug 25, 2021 |
| FOLFOX Regimen | Phase 1 | Phase 1 | 1 | 1 | 0 | 2 | 0 | — | — | Nov 15, 2013 |
| Futibatinib | Phase 1 | Phase 1 | 1 | 1 | 0 | 2 | 0 | — | — | Jun 1, 2021 |
| Anvumetostat | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Sep 17, 2024 |
| Inavolisib | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Jul 29, 2020 |
| Mobocertinib | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Feb 4, 2019 |
| Pan-RAF/MEK Molecular Glue NST-628 | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 9, 2024 |
| Sonidegib | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Feb 13, 2020 |
| Tazemetostat | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Jul 27, 2022 |
| Panobinostat | Phase 1 | Phase 1 | 0 | 0 | 0 | 5 | 0 | — | — | 2007-11 |
| Pilaralisib | Phase 1 | Phase 1 | 0 | 0 | 0 | 3 | 0 | — | — | 2008-05 |
| Mogamulizumab | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2015-01 |
| Samotolisib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Jul 31, 2012 |
| Temoporfin | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2012-07 |
| 2-Deoxy-D-glucose | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-02 |
| Abexinostat | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 20, 2018 |
| Agerafenib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 14, 2018 |
| Alvocidib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 25, 2004 |
| Aurora A Kinase Inhibitor LY3295668 Erbumine | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 16, 2019 |
| AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 1, 2017 |
| Belinostat | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 1, 2009 |
| Birabresib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | May 4, 2016 |
| Bosutinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 10, 2019 |
| Busulfan | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 1999-09 |
| Canertinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2002-12 |
| Chloroquine | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2014-05 |
| Dacarbazine | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 14, 2007 |
| Hydroxyurea | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 1995-07 |
| Immunomodulatory Oligonucleotide | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-11 |
| Interferon Alfacon-1 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-07 |
| Letrozole | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 31, 2012 |
| Margetuximab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 18, 2017 |
| Momelotinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 11, 2015 |
| Pacritinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | May 18, 2015 |
| Pan-RAF Inhibitor LY3009120 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 26, 2013 |
| Quisinostat | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-08 |
| Ridaforolimus | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-09 |
| Rituximab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 21, 2011 |
| Tanespimycin | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 1999-07 |
| Tunlametinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | May 21, 2020 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.